• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Apogee Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/11/25 7:15:29 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APGE alert in real time by email
    8-K
    0001974640false00019746402025-08-112025-08-11

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 11, 2025

     

     

    Apogee Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41740

    93-4958665

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    221 Crescent St., Bldg 17, Suite 102b

     

    Waltham, Massachusetts

     

    02453

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (650) 394-5230

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.00001 per share

     

    APGE

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On August 11, 2025, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 (the “Earnings Press Release”).

    A copy of the Earnings Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated by reference herein. The exhibit furnished under Item 2.02 of this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in such filing.

     

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits. The following exhibits are being furnished herewith:

    EXHIBIT INDEX

    Exhibit
    No.

     

    Description

     

     

    99.1

     

    Earnings Press Release, dated August 11, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Apogee Therapeutics, Inc.

     

     

     

     

    Date:

    August 11, 2025

    By:

    /s/ Michael Henderson, M.D.

     

     

     

    Michael Henderson, M.D.
    Chief Executive Officer

     


    Get the next $APGE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGE

    DatePrice TargetRatingAnalyst
    7/7/2025$100.00 → $115.00Buy
    BTIG Research
    3/13/2025$95.00Buy
    Citigroup
    11/25/2024$89.00Buy
    Canaccord Genuity
    5/10/2024$80.00Buy
    BofA Securities
    12/20/2023$43.00Buy
    BTIG Research
    8/8/2023Outperform
    TD Cowen
    8/8/2023$40.00Outperform
    Wedbush
    8/8/2023$29.00Buy
    Guggenheim
    More analyst ratings

    $APGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Dambkowski Carl sold $102,950 worth of shares (2,725 units at $37.78), decreasing direct ownership by 1% to 236,273 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    8/8/25 8:00:15 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Dambkowski Carl exercised 7,365 shares at a strike of $22.86 and sold $454,954 worth of shares (10,090 units at $45.09), decreasing direct ownership by 1% to 238,998 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    7/3/25 8:00:07 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Fairmount Funds Management Llc

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    6/20/25 8:06:44 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    SEC Filings

    View All

    SEC Form 10-Q filed by Apogee Therapeutics Inc.

    10-Q - Apogee Therapeutics, Inc. (0001974640) (Filer)

    8/11/25 7:30:50 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)

    8/11/25 7:15:29 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.

    SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    8/6/25 11:51:35 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on Apogee Therapeutics with a new price target

    BTIG Research reiterated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $115.00 from $100.00 previously

    7/7/25 11:34:24 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Apogee Therapeutics with a new price target

    Citigroup initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $95.00

    3/13/25 7:25:29 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Canaccord Genuity initiated coverage on Apogee Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $89.00

    11/25/24 7:29:35 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    12/16/24 6:00:10 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

    Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3- or 6-month maintenance dosing, a significant improvement versus standard of care which is dosed every two weeks, is ongoing with 52-week readout anticipated in 1H 2026 Driven by strong enrollment, APEX Phase 2 Part B of APG777 readout accelerated to mid-2026 First patient dosed in Phase 1b head-to-head trial of APG279 (IL-13 + OX40L) vs. DUPIXENT in atopic dermatitis, with readout expected in 2H 2026 $621.2 million cash, cash equivalents and marketable securities suppor

    8/11/25 7:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

    APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo-adjusted efficacy of any biologic in a global study Exposure-response relationship observed across multiple key endpoints; APEX Part B is testing higher exposures with readout accelerated and now anticipated mid-2026, enabling planned Phase 3 initiation in 2026 APEX Part A testing potentially best in class 3- or 6-month maintenance dosing with 52-week readout anticipated 1H 2026 APG777 was well tolerated with a favorable safety profi

    7/7/25 6:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

    SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Detai

    7/6/25 6:00:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Leadership Updates

    Live Leadership Updates

    View All

    Apogee Therapeutics Announces Agenda for Virtual R&D Day

    SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t

    11/29/24 1:00:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

    SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024. The event will include presentations from management discussing updates across Apogee's programs, highlighting APG777's best-in-class potential in AD, the significant role of

    11/18/24 7:30:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

    SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy,

    9/9/24 7:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

    SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 5:46:11 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Apogee Therapeutics Inc.

    SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 11:16:12 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

    SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 10:18:32 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    Financials

    Live finance-specific insights

    View All

    Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

    APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline and placebo-adjusted efficacy of any biologic in a global study Exposure-response relationship observed across multiple key endpoints; APEX Part B is testing higher exposures with readout accelerated and now anticipated mid-2026, enabling planned Phase 3 initiation in 2026 APEX Part A testing potentially best in class 3- or 6-month maintenance dosing with 52-week readout anticipated 1H 2026 APG777 was well tolerated with a favorable safety profi

    7/7/25 6:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

    SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Detai

    7/6/25 6:00:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

    SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for i

    2/28/25 4:00:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care